// App-Quantinova.ai

BSH19‐PO‐001 : Combining Sulfasalazine with Parthenolide to Prevent Chemoresistance in B Cell Precursor ALL

Researchers

Presenter

  • P. Diamanti

Principal Investigators

  • A. Al-Masri

  • B. Ede

  • A. Blair

Medical Centers

  • Bristol Institute for Transfusion Sciences, NHS Blood & Transplant

  • University of Bristol, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Annexin V

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 34

  • Coxsackie Virus And Adenovirus Receptor

  • Proto-oncogene tyrosine-protein kinase ROS

  • Mesenchymal stem cells

Drug/Treatment

  • Sulfasalazine

  • Cysteine Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved